-
-
- R&D Unit
- Industrial Vaccine Production Unit
- Vaccine and Immunization Training Unit
- Vaccine Epidemiology Unit
- Preclinical and Clinical Research and Project Coordination Unit
- Epidemiology of Pandemic-Risk Infectious Agents Unit
- Bioterrorism Unit
- Laboratory Animal Production/Testing and Preclinical Research Unit
- Tissue Culture Collection, Viral and Bacterial Culture Banking Unit
- Quality Control Laboratory Unit
- Training, Administrative, and Financial Services Unit
-
-
-
- Announcements
- Key Dates
- FAQ
- Contact
Turkovac Clinical Trials Booster Phase IIB
TSB-VAC-COV-TUR-RF2B.05
"A Single-Arm, Open-Label, Multi-Centre, Phase 2b Clinical Study to Determine the Efficacy, Safety, and Immunogenicity of Booster Vaccination (TURKOVAC) Against SARS-CoV-2"
The aim of this study, the primary objective of the study is to evaluate the efficacy of the booster dose of the TURKOVAC vaccine administered to volunteers who have passed at least 180 days and at most 240 days after the 2nd dose of the Comirnaty (Code name: BNT162b2) vaccine was administered. Efficacy will be evaluated on days 28 and 84 with spike-specific antibody response and neutralizing antibody levels. The secondary objective of the study is to evaluate the safety of the TURKOVAC vaccine in volunteers, to evaluate the safety of the TURKOVAC vaccine in volunteers. The study, which began with the recruitment of the first volunteer on 24.01.2022, continues with the follow-ups of 64 volunteers from the study where the last volunteer was recruited on 17.08.2022. As the study is ongoing, the conclusion section will be shared when the study is completed.